Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare in children with only a few SDHB mutation-related cases. Previous studies on children were conducted in small cohorts. This large set of pediatric patients provides robust data in the evaluation of clinical outcomes.
Sixty-four pediatric PHEO/PGL patients with SDHB germline mutations were included in the present study. The clinical presentation, disease course, and survival rate were evaluated.
Thirty-eight males and 26 females were diagnosed with PHEO/PGL at a median age of 13 years. The majority of patients displayed norepinephrine hypersecretion and 73.44% initially presented with a solitary tumor. Metastases developed in 70% of patients at the median age of 16 years and were mostly diagnosed first 2 years and in years 12–18 post-diagnosis. The presence of metastases at the time of diagnosis had a strong negative impact on survival in males but not in females. The estimated 5-, 10-, and 20-year survival rates were 100%, 97.14%, and 77.71%, respectively.
The present report has highlighted several important aspects in the management of pediatric patients with SDHB mutations associated-PHEO/PGL. Initial diagnostic evaluation of SDHB mutation carriers should be started at age of 5–6 years with initial work-up focusing on abdominal region. Thorough follow-up is crucial first 2 years post-diagnosis and more frequent follow-ups are needed in years 10–20 post-diagnosis due to the increased risk of metastases. Although this age group developed metastasis as early as 5 years from diagnosis, we have shown that the overall 20-year prognosis and survival are good.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Amar L, Bertherat J, Baudin E et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812–8818. https://doi.org/10.1200/JCO.2005.03.1484
Amar L, Baudin E, Burnichon N et al (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92:3822–3828. https://doi.org/10.1210/jc.2007-0709
Armstrong R, Sridhar M, Greenhalgh KL et al (2008) Phaeochromocytoma in children. Arch Dis Child 93:899–904. https://doi.org/10.1136/adc.2008.139121
Assadipour Y, Sadowski SM, Alimchandani M et al (2017) SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery 161:230–239. https://doi.org/10.1016/j.surg.2016.05.050
Babic B, Patel D, Aufforth R et al (2017) Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery 161:220–227. https://doi.org/10.1016/j.surg.2016.05.059
Barontini M, Levin G, Sanso G (2006) Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann NY Acad Sci 1073:30–37. https://doi.org/10.1196/annals.1353.003
Bausch B, Wellner U, Bausch D et al (2014) Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 21:17–25. https://doi.org/10.1530/ERC-13-0415
Baysal BE, Willett-Brozick JE, Lawrence EC et al (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178–183. https://doi.org/10.1136/jmg.39.3.178
Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA (2004) Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 28:592–596. https://doi.org/10.1007/s00268-004-7134-9
Benn DE, Gimenez-Roqueplo AP, Reilly JR et al (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:827–836. https://doi.org/10.1210/jc.2005-1862
Bissada NK, Safwat AS, Seyam RM et al (2008) Pheochromocytoma in children and adolescents: a clinical spectrum. J Pediatr Surg 43:540–543. https://doi.org/10.1016/j.jpedsurg.2007.10.038
Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–4509. https://doi.org/10.1210/jc.2006-0423
Cascon A, Inglada-Pérez L, Comino-Méndez I et al (2013) Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocr Relat Cancer 20:L1–6. https://doi.org/10.1530/ERC-12-0339
Choat H, Derrevere K, Knight L, Brown W, Mack EH (2014) SDHB-associated paraganglioma in a pediatric patient and literature review on hereditary pheochromocytoma-paraganglioma syndromes. Case Rep Endocrinol 2014:502734. https://doi.org/10.1155/2014/502734
Ciftci AO, Tanyel FC, Senocak ME, Buyukpamukcu N (2001) Pheochromocytoma in children. J Pediatr Surg 36:447–452. https://doi.org/10.1053/jpsu.2001.21612
Comino-Mendez I, Gracia-Aznárez FJ, Schiavi F et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43:663–667. https://doi.org/10.1038/ng.861
Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K (2019) Genotype-phenotype correlations in pheochromocytoma and paraganglioma. Endocr Relat Cancer. https://doi.org/10.1530/ERC-19-0024
Darr R, Zöphel K, Eisenhofer G et al (2012) Combined use of 68Ga-DOTATATE and 18F-FDG PET/CT to localize a bronchial carcinoid associated with ectopic ACTH syndrome. J Clin Endocrinol Metab 97:2207–2208. https://doi.org/10.1210/jc.2012-1402
De Krijger RR, Van Nederveen FH, Korpershoek E, De Herder WW, De Muinck Keizer-Schrama SM, Dinjens WN (2006) Frequent genetic changes in childhood pheochromocytomas. Ann NY Acad Sci 1073:166–176. https://doi.org/10.1196/annals.1353.017
Ein SH, Shandling B, Wesson D, Filler R (1990) Recurrent pheochromocytomas in children. J Pediatr Surg 25:1063–1065. https://doi.org/10.1016/0022-3468(90)90219-y
Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181–193. https://doi.org/10.1016/j.ccell.2017.01.001
Gimenez-Roqueplo AP, Favier J, Rustin P et al (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615–5621
Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44(5):328–333. https://doi.org/10.1055/s-0031-1301302
Hensen EF, Bayley JP (2011) Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Fam Cancer 10:355–363. https://doi.org/10.1007/s10689-010-9402-1
Hescot S, Curras-Freixes M, Deutschbein T et al (2019) Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab 104:2367–2374. https://doi.org/10.1210/jc.2018-01968
Jha A, Ling A, Millo C et al (2018) Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45:787–797. https://doi.org/10.1007/s00259-017-3896-9
Jochmanova I, Wolf KI, King KS et al (2017) SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol 143:1421–1435. https://doi.org/10.1007/s00432-017-2397-3
Kaufman BH, Telander RL, van Heerden JA, Zimmerman D, Sheps SG, Dawson B (1983) Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 18:879–884. https://doi.org/10.1016/s0022-3468(83)80040-2
King KS, Prodanov T, Kantorovich V et al (2011) Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 29:4137–4142. https://doi.org/10.1200/JCO.2011.34.6353
Kong G, Grozinsky-Glasberg S, Hofman MS et al (2017) Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab 102:3278–3287. https://doi.org/10.1210/jc.2017-00816
Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs WHO/IARC classification of Tumours, 4th edn. International Agency for Research on Cancer, Lyon
Maher ER, Eng C (2002) The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11(2347–2354):1. https://doi.org/10.1093/hmg/11.20.2347
Mei L, Khurana A, Al-Juhaishi T, Faber A, Celi F, Smith S, Boikos S (2019) Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review. Horm Metab Res 51:451–457. https://doi.org/10.1055/a-0851-3275
Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466. https://doi.org/10.1056/NEJMoa020152
Neumann HP, Pawlu C, Peczkowska M (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951. https://doi.org/10.1001/jama.292.8.943
Niemeijer ND, Rijken JA, Eijkelenkamp K et al (2017) The phenotype of SDHB germline mutation carriers: a nationwide study. Eur J Endocrinol 177:115–125. https://doi.org/10.1530/EJE-17-0074
Pamporaki C, Därr R, Bursztyn M et al (2013) Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma. Clin Endocrinol (Oxf) 79:476–483. https://doi.org/10.1111/cen.12191
Pham TH, Moir C, Thompson GB et al (2006) Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 118:1109–1117. https://doi.org/10.1542/peds.2005-2299
Rijken JA, Niemeijer ND, Corssmit EP, Jonker MA, Leemans CR, Menko FH, Hensen EF (2016) Low penetrance of paraganglioma and pheochromocytoma in an extended kindred with a germline SDHB exon 3 deletion. Clin Genet 89:128–132. https://doi.org/10.1111/cge.12591
Ross JH (2000) Pheochromocytoma. Special considerations in children. Urol Clin N Am 27:393–402. https://doi.org/10.1016/s0094-0143(05)70088-4
Schovanek J, Martucci V, Wesley R et al (2014) The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer 14:523. https://doi.org/10.1186/1471-2407-14-523
Solis DC, Burnichon N, Timmers HJ et al (2009) Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clin Genet 75:354–363. https://doi.org/10.1111/j.1399-0004.2009.01157.x
Spoudeas HA (ed) (2005) Paediatric endocrine tumours. A multi-disciplinary consensus statement of best practice from a working group convened under the auspices of the BSPED and UKCCSG (rare tumour working groups). Novo Nordisk Ltd, West Sussex
Stackpole RH, Melicow MM, Uson AC (1963) Pheochromocytoma in children Report of 9 case and review of the first 100 published cases with follow-up studies. J Pediatr 63:314–330. https://doi.org/10.1016/s0022-3476(63)80345-5
Timmers HJ, Kozupa A, Eisenhofer G et al (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92:779–786. https://doi.org/10.1210/jc.2006-2315
Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K (2009) Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 16:391–400. https://doi.org/10.1677/ERC-08-0284
Turkova H, Prodanov T, Maly M et al (2016) Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma/paraganglioma: an national institutes of health study. Endocr Pract 22:302–314. https://doi.org/10.4158/EP15725.OR
Vicha A, Musil Z, Pacak K (2013) Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes 20:186–191. https://doi.org/10.1097/MED.0b013e32835fcc45
This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver NICHD, NIH (Grant Z1AHD008735).
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed assent from the patients and signed permission from one or both parents were obtained for all the individual participants included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jochmanova, I., Abcede, A.M.T., Guerrero, R.J.S. et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol (2020). https://doi.org/10.1007/s00432-020-03138-5
- SDHB mutation
- Pediatric oncology